175 related articles for article (PubMed ID: 17606720)
1. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer.
Kim JH; Bogner PN; Ramnath N; Park Y; Yu J; Park YM
Clin Cancer Res; 2007 Jul; 13(13):3875-82. PubMed ID: 17606720
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target.
Kim JH; Bogner PN; Baek SH; Ramnath N; Liang P; Kim HR; Andrews C; Park YM
Clin Cancer Res; 2008 Apr; 14(8):2326-33. PubMed ID: 18413821
[TBL] [Abstract][Full Text] [Related]
3. The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small-cell lung cancer.
Yang H; Wang W; Zhang Y; Zhao J; Lin E; Gao J; He J
Clin Lung Cancer; 2011 May; 12(3):166-71. PubMed ID: 21663859
[TBL] [Abstract][Full Text] [Related]
4. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer.
Zhang Z; Ma J; Li N; Sun N; Wang C
Ann Thorac Surg; 2006 Jul; 82(1):243-8. PubMed ID: 16798222
[TBL] [Abstract][Full Text] [Related]
5. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
6. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
7. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology.
Kim YJ; Ahn JY; Liang P; Ip C; Zhang Y; Park YM
Cancer Res; 2007 Jan; 67(2):546-54. PubMed ID: 17234762
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.
Herbst RS; Yano S; Kuniyasu H; Khuri FR; Bucana CD; Guo F; Liu D; Kemp B; Lee JJ; Hong WK; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):790-7. PubMed ID: 10741698
[TBL] [Abstract][Full Text] [Related]
9. Dual-negative expression of Nrf2 and NQO1 predicts superior outcomes in patients with non-small cell lung cancer.
Tong YH; Zhang B; Yan YY; Fan Y; Yu JW; Kong SS; Zhang D; Fang L; Su D; Lin NM
Oncotarget; 2017 Jul; 8(28):45750-45758. PubMed ID: 28501854
[TBL] [Abstract][Full Text] [Related]
10. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of microRNA-181b is a potential prognostic marker of non-small cell lung cancer.
Yang J; Liu H; Wang H; Sun Y
Pathol Res Pract; 2013 Aug; 209(8):490-4. PubMed ID: 23827213
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
14. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome.
Zhang L; Chen J; Ke Y; Mansel RE; Jiang WG
Int J Mol Med; 2006 May; 17(5):937-44. PubMed ID: 16596284
[TBL] [Abstract][Full Text] [Related]
15. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer.
Yu CJ; Shun CT; Yang PC; Lee YC; Shew JY; Kuo SH; Luh KT
Am J Respir Crit Care Med; 1997 Apr; 155(4):1419-27. PubMed ID: 9105088
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of survivin and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery.
Tang XP; Li J; Yu LC; Chen YC; Shi SB; Zhu LR; Chen P
Lung Cancer; 2013 Aug; 81(2):273-9. PubMed ID: 23756092
[TBL] [Abstract][Full Text] [Related]
17. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
18. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
19. [CXCR4 and Nrf2 expressions in non-small cell lung cancer and their clinical implications].
Hu T; Yao Y; Yu S; Guo H; Tian T; Han L; Wang W; Guo Q; Wang J; Nan K; Wang S
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):153-8. PubMed ID: 24589587
[TBL] [Abstract][Full Text] [Related]
20. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.
Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
